Identification

Name
Ergoloid mesylate
Accession Number
DB01049  (APRD00711, DB01287)
Type
Small Molecule
Groups
Approved
Description

Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.[1] All these components are produced by the fungus Claviceps purpurea and are all derivatives of the tetracyclic compound 6-methylergonovine.[7] The derivatives of this fungus are identified to be about 350 different substances from which the components of the ergoloid mesylate mixture are composed of the dihydrogenated ergot alkaloid derivatives.[3] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued.[9]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA.[10] To know more about the individual components of the ergoloid mixture, please visit Epicriptine, Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.

Synonyms
  • co-dergocrine mesilate
  • co-dergocrine mesylate
  • co-dergocrine methanesulfonate
  • codergocrine mesilate
  • codergocrine mesylate
  • codergocrine methanesulfonate
  • Dihydroergotoxine Mesilate
  • Dihydroergotoxine Mesylate
  • dihydroergotoxine methanesulfonate
  • Dihydroergotoxine Methanesulfonate
  • dihydroergotoxine methanesulfonates
  • dihydroergotoxine monomethanesulfonate
  • dihydrogenated ergot alkaloids
  • Ergoloid Mesilates
  • Ergoloid Mesylates
  • ergoloid methanesulfonate
  • ergoloid methanesulfonates
  • hydrogenated ergot alkaloids
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hydergine Tablets, 1mgTablet1 mgOralSterimax Inc1968-12-31Not applicableCanada
International/Other Brands
Alkergot (Eon Labs) / Circanol (3M) / Deapril (Bristol Myers Squibb) / Gerimal / Hydergine (Novartis)
Categories
UNII
X3S33EX3KW
CAS number
8067-24-1
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

It was labeled by the FDA for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible condition[2] as well as for age-related cognitive impairment.[4] The prescription of this drug is conditioned to the corroboration that the patient is not suffering from a potentially reversible and treatable condition especially delirium and dementiform illness secondary to systemic disease, primary neurological disease or primary mood disturbance.[11] To know more about the individual components of the ergoloid mixture, please visit Dihydroergocristine and Dihydro-alpha-ergocryptine

Structured Indications
Pharmacodynamics

The mechanism of action of ergoloid mesylate is not completely established but it is thought that it increases both the blood flow and cerebral metabolism. Some studies have shown a significant improvement in alertness and memory, as well as a decline in confusion while some other benefits have shown a lack of effect.[2] Its action produces a damper in the impulses from the vasomotor center which reduces the vascular tone which translates in the slow of pulse rate, prevention of compensatory tachycardia.[3] To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.

Mechanism of action

The general mechanism of action of ergoloid mesylate is the dual action of partial agonism/antagonism of adrenergic, dopaminergic and serotonergic receptors. The pharmacological activity is determined by the degree of activity of each component at the receptor site.[7] To know more about the individual components of the ergoloid mixture, please visit Epicriptine, Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.

TargetActionsOrganism
ADopamine receptor
antagonist
agonist
Human
AAlpha adrenergic receptor
antagonist
agonist
Human
ABeta adrenergic receptor
antagonist
agonist
Human
ASerotonin Receptors
antagonist
agonist
Human
Absorption

The maximal plasma concentration of the components of the mixture of ergoloid mesylates is approximately 0.04 mcg/l. The analysis of the concentration of the major metabolites of each component indicates that all ergoloid mesylate are rapidly transformed after absorption. This finding is supported as they were found in one order of magnitude higher in concentration when compared to the original form.[3] Ergoloid mesylate seems to have a very low absorption of only 25%. From this absorption by the GI tract, approximately 50% of the absorbed dose is eliminated by first-pass metabolism. After absorption, the maximal plasma concentration is attained after 3-4 hours and the oral bioavailability is very low.[6] Simultaneous food ingestion has no effect on the extent of absorption but it does lower the absorption rate.[5] To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.

Volume of distribution

The volume of distribution is about 2 L/kg.[7] To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine and Dihydroergocristine.

Protein binding

Ergoloid mesylate presents a very large plasma protein binding that accounts for 81% of the administered dose.[13] To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine and Dihydroergocristine.

Metabolism

Most of the metabolism of ergoloid mesylate is hepatic and it is performed very rapidly after absorption. After exposition in vitro, the major metabolites identified are hydroxy-dihydroergocornine, hydroxy-dihydroergocryptine and hydroxy-dihydroergocristine.[4] All metabolic transformations seem to be related to the activity of the cytochrome CYP3A4.[12] To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.

Route of elimination

The ergoloid mesylate mixture is mainly excreted via bile in feces. The ratio of the eliminated dose via urine after intravenous and oral administration is 8.4% and 2% respectively.[6] Urinary excretion of the unchanged drug is very small and bile excretion is represented mainly by ergot metabolites conformed as conjugated compounds.[T191] To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.

Half life

The reported plasma half-life of ergoloid mesylate is 3.5 hours while the terminal half-life is of 13 hours.[6] To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine.

Clearance

To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine and Dihydroergocristine.

Toxicity

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia. The excessive use of ergoloid mesylate can lead to ergotism.[7] To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Ergoloid mesylate can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Ergoloid mesylate can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Ergoloid mesylate can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AcebutololAcebutolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acetophenazine.Approved
Acetyl sulfisoxazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdrafinilErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Adrafinil.Withdrawn
AlmotriptanErgoloid mesylate may increase the vasoconstricting activities of Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Ergoloid mesylate can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprenololAlprenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Withdrawn
AmibegronErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Amibegron.Investigational
AmiodaroneThe metabolism of Ergoloid mesylate can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amisulpride.Approved, Investigational
AmitrazErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ergoloid mesylate.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergoloid mesylate.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Amprenavir.Approved, Investigational
AnisodamineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Anisodamine.Investigational
Antithrombin III humanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Antithrombin III human.Approved
ApalutamideThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Apixaban.Approved
ApomorphineErgoloid mesylate may increase the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Apraclonidine.Approved
AprepitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Ergoloid mesylate can be increased when it is combined with Aprotinin.Approved, Investigational, Withdrawn
ArbutamineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Arbutamine.Approved
ArformoterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the vasoconstricting activities of Ergoloid mesylate.Investigational
AsenapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Asenapine.Approved
AsunaprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
AtomoxetineThe metabolism of Ergoloid mesylate can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Azaperone.Investigational, Vet Approved
BatimastatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Batimastat.Experimental
BefunololErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Befunolol.Experimental
BenazeprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benazepril.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Benperidol.Approved, Investigational
BenzamidineThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benzamidine.Experimental
BetaxololBetaxolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
BevantololBevantolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bifeprunox.Investigational
BisoprololBisoprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BitolterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BortezomibThe metabolism of Ergoloid mesylate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Brexpiprazole.Approved, Investigational
BrimonidineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Brimonidine.Approved
BromocriptineErgoloid mesylate may increase the vasoconstricting activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bromperidol.Approved, Investigational
BucindololBucindolol may increase the vasoconstricting activities of Ergoloid mesylate.Investigational
BufuralolBufuralol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental, Investigational
BupranololBupranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergoloid mesylate.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Butaperazine.Experimental
CabergolineErgoloid mesylate may increase the vasoconstricting activities of Cabergoline.Approved
CamostatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Ergoloid mesylate can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Carbomycin.Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cariprazine.Approved, Investigational
CarteololCarteolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
CarvedilolCarvedilol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
CeliprololCeliprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
CeritinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ceritinib.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholesterolThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cholesterol.Approved, Experimental, Investigational
ChymostatinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilastatin.Approved, Investigational
CilazaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilazapril.Approved
CirazolineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergoloid mesylate.Approved
ClarithromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ergoloid mesylate can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clozapine.Approved
CobicistatThe metabolism of Ergoloid mesylate can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ergoloid mesylate.Approved, Investigational
CrizotinibThe metabolism of Ergoloid mesylate can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergoloid mesylate.Approved
CyclosporineThe metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dapiprazole.Approved
DarexabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Darexaban.Investigational
DarunavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Ergoloid mesylate can be decreased when combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desipramine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desvenlafaxine.Approved, Investigational
DetomidineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergoloid mesylate.Approved
DihydroergotamineErgoloid mesylate may increase the vasoconstricting activities of Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Ergoloid mesylate can be decreased when combined with Diltiazem.Approved, Investigational
DipivefrinErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Dipivefrin.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dixyrazine.Experimental
DobutamineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Ergoloid mesylate.Approved, Investigational
DopexamineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Dopexamine.Approved, Investigational
DoxepinThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Doxepin.Approved, Investigational
DoxycyclineThe metabolism of Ergoloid mesylate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Ergoloid mesylate can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Droperidol.Approved, Vet Approved
DroxidopaErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergoloid mesylate.Approved
EcabetThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ecabet.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Elafin.Investigational
EletriptanErgoloid mesylate may increase the vasoconstricting activities of Eletriptan.Approved, Investigational
EnalaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental
EphedrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Ephedrine.Approved
Epigallocatechin GallateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Epinephrine.Approved, Vet Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ergonovine.Approved
ErgotamineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Ergotamine.Approved
ErythromycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Escitalopram.Approved, Investigational
EsmololEsmolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
EtilefrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Etilefrine.Withdrawn
FaldaprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Faldaprevir.Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergoloid mesylate.Approved, Illicit, Investigational, Vet Approved
FluanisoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Fluconazole.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergoloid mesylate.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluspirilene.Approved, Investigational
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ergoloid mesylate.Approved, Investigational
FormoterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Ergoloid mesylate can be increased when combined with Fosphenytoin.Approved, Investigational
FrovatriptanErgoloid mesylate may increase the vasoconstricting activities of Frovatriptan.Approved, Investigational
Fusidic AcidThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Geldanamycin.Experimental, Investigational
GM6001The serum concentration of Ergoloid mesylate can be increased when it is combined with GM6001.Experimental
GranisetronGranisetron may increase the serotonergic activities of Ergoloid mesylate.Approved, Investigational
GuanabenzErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Guanfacine.Approved, Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Haloperidol.Approved
HexoprenalineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Higenamine.Investigational
IdelalisibThe metabolism of Ergoloid mesylate can be decreased when combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Ergoloid mesylate can be increased when it is combined with Idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Iloperidone.Approved
ImatinibThe metabolism of Ergoloid mesylate can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergoloid mesylate.Approved
IndenololIndenolol may increase the vasoconstricting activities of Ergoloid mesylate.Withdrawn
IndinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Indinavir.Approved
IsavuconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Ergoloid mesylate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Isocarboxazid.Approved
IsoetarineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Isoetarine.Approved
IsoflurophateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoprenalineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Ergoloid mesylate can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ixazomib.Approved, Investigational
JosamycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Josamycin.Approved, Investigational
KetoconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
LandiololLandiolol may increase the vasoconstricting activities of Ergoloid mesylate.Investigational
LepirudinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Letaxaban.Investigational
LevobunololLevobunolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levomilnacipran.Approved, Investigational
LinagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ergoloid mesylate.Approved, Investigational
LisinoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideErgoloid mesylate may increase the vasoconstricting activities of Lisuride.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lithium.Approved
LofexidineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lopinavir.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergoloid mesylate.Approved
LorpiprazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Ergoloid mesylate can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ergoloid mesylate can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergoloid mesylate.Approved, Investigational
MedetomidineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Medetomidine.Vet Approved
MelagatranThe serum concentration of Ergoloid mesylate can be increased when it is combined with Melagatran.Experimental
MelperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Melperone.Approved, Investigational
MephentermineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mesoridazine.Approved, Investigational
MetaraminolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Metaraminol.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ergoloid mesylate.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methotrimeprazine.Approved, Investigational
MethoxamineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Methoxyphenamine.Experimental
MethyldopaErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Methyldopa.Approved
MetipranololMetipranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Metoclopramide.Approved, Investigational
MetoprololMetoprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
MidodrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Midodrine.Approved
MifepristoneThe serum concentration of Ergoloid mesylate can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Milnacipran.Approved, Investigational
MirabegronErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ergoloid mesylate.Approved
MitotaneThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Mitotane.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Moclobemide.Approved, Investigational
MoexiprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Moperone.Experimental
MosapramineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mosapramine.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Ergoloid mesylate can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololNadolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
NafamostatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Nafamostat.Approved, Investigational
NaluzotanErgoloid mesylate may increase the vasoconstricting activities of Naluzotan.Investigational
NaphazolineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Naphazoline.Approved
NaratriptanErgoloid mesylate may increase the vasoconstricting activities of Naratriptan.Approved, Investigational
NebivololErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Ergoloid mesylate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Ergoloid mesylate can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Ergoloid mesylate can be decreased when combined with Nilotinib.Approved, Investigational
NitroaspirinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinThe bioavailability of Ergoloid mesylate can be increased when combined with Nitroglycerin.Approved, Investigational
NorepinephrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Norepinephrine.Approved
NorfenefrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Norfenefrine.Experimental
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ergoloid mesylate.Approved
NylidrinErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
OctopamineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Octopamine.Experimental
OlanzapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Ergoloid mesylate can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Oleandomycin.Vet Approved
OlodaterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Olodaterol.Approved
OmapatrilatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Omapatrilat.Investigational
OndansetronOndansetron may increase the serotonergic activities of Ergoloid mesylate.Approved
OrciprenalineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Otamixaban.Investigational
OxprenololOxprenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
OxyfedrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxypertineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Oxypertine.Experimental
PalbociclibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Ergoloid mesylate.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergoloid mesylate.Approved, Investigational
PenbutololPenbutolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Penfluridol.Experimental
PentobarbitalThe metabolism of Ergoloid mesylate can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perazine.Approved, Investigational
PergolideErgoloid mesylate may increase the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergoloid mesylate.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ergoloid mesylate.Approved
PhenobarbitalThe metabolism of Ergoloid mesylate can be increased when combined with Phenobarbital.Approved, Investigational
PhenylephrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Ergoloid mesylate can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Ergoloid mesylate can be increased when it is combined with Phosphoramidon.Experimental
PiclozotanErgoloid mesylate may increase the vasoconstricting activities of Piclozotan.Investigational
PimozideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pimozide.Approved
PindololPindolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipotiazine.Approved, Investigational
PirbuterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Pirbuterol.Approved
PitolisantThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorPlatelet Activating Factor may increase the vasoconstricting activities of Ergoloid mesylate.Experimental
PosaconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
PrenalterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Prenalterol.Experimental
PrimidoneThe metabolism of Ergoloid mesylate can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Prinomastat.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Procarbazine.Approved, Investigational
ProcaterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promethazine.Approved, Investigational
PropericiazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Propericiazine.Approved, Investigational
PropranololPropranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergoloid mesylate.Approved
PseudoephedrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Quetiapine.Approved
QuinaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Quinapril.Approved, Investigational
RacecadotrilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Racecadotril.Investigational
RacepinephrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Raclopride.Investigational
RactopamineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Ergoloid mesylate can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Rasagiline.Approved
RemikirenThe serum concentration of Ergoloid mesylate can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Remoxipride.Approved, Withdrawn
ReproterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Reserpine.Approved, Investigational
RifabutinThe metabolism of Ergoloid mesylate can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Ergoloid mesylate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ergoloid mesylate can be increased when combined with Rifapentine.Approved, Investigational
RilmenidineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Rimiterol.Experimental
RisperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ritanserin.Investigational
RitobegronErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Ritobegron.Investigational
RitodrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Rivaroxaban.Approved
RizatriptanErgoloid mesylate may increase the vasoconstricting activities of Rizatriptan.Approved
RomifidineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Romifidine.Vet Approved
RopiniroleErgoloid mesylate may increase the vasoconstricting activities of Ropinirole.Approved, Investigational
RoxithromycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Ergoloid mesylate can be decreased when combined with Rucaparib.Approved, Investigational
S-3304The serum concentration of Ergoloid mesylate can be increased when it is combined with S-3304.Investigational
SalbutamolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved
SaquinavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Saxagliptin.Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ergoloid mesylate.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertraline.Approved
SildenafilThe metabolism of Ergoloid mesylate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Sivelestat.Investigational
SolabegronErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Solabegron.Investigational
SolithromycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Solithromycin.Investigational
SotalolSotalol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
SpiraprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Ergoloid mesylate can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Ergoloid mesylate can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sultopride.Experimental
SumatriptanErgoloid mesylate may increase the vasoconstricting activities of Sumatriptan.Approved, Investigational
SynephrineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Synephrine.Experimental
TalinololTalinolol may increase the vasoconstricting activities of Ergoloid mesylate.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Ergoloid mesylate.Approved
TelaprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Telithromycin.Approved
TemocaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Temocapril.Experimental, Investigational
TerbutalineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Terbutaline.Approved
TertatololTertatolol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tetrahydropalmatine.Investigational
ThiopropazateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioridazine.Approved, Withdrawn
ThiorphanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiothixene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Ergoloid mesylate can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
TipranavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Tocilizumab.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergoloid mesylate.Approved, Investigational
TrandolaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergoloid mesylate.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergoloid mesylate.Approved, Investigational
TretoquinolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Tretoquinol.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ergoloid mesylate.Approved
TropisetronTropisetron may increase the serotonergic activities of Ergoloid mesylate.Approved, Investigational
TulobuterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Tulobuterol.Investigational
TylosinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ulinastatin.Investigational
VemurafenibThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ergoloid mesylate.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Veralipride.Experimental
VerapamilThe metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.Approved
VilazodoneErgoloid mesylate may increase the vasoconstricting activities of Vilazodone.Approved
VildagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Vildagliptin.Approved, Investigational
VoriconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineErgoloid mesylate may increase the vasoconstricting activities of Vortioxetine.Approved, Investigational
XamoterolErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Xamoterol.Experimental
XimelagatranThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Xylazine.Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Ergoloid mesylate can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZiprasidoneThe metabolism of Ergoloid mesylate can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Zofenopril.Experimental
ZolmitriptanErgoloid mesylate may increase the vasoconstricting activities of Zolmitriptan.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Thompson TL 2nd, Filley CM, Mitchell WD, Culig KM, LoVerde M, Byyny RL: Lack of efficacy of hydergine in patients with Alzheimer's disease. N Engl J Med. 1990 Aug 16;323(7):445-8. doi: 10.1056/NEJM199008163230704. [PubMed:2082953]
  2. Delagarza VW: New drugs for Alzheimer's disease. Am Fam Physician. 1998 Oct 1;58(5):1175-82. [PubMed:9787282]
  3. PERCHESON PB, CARROLL JJ: The use of hydergine in obstetrics. Can Med Assoc J. 1954 Dec;71(6):588-94. [PubMed:13209453]
  4. Bicalho B, Giolo JM, Lilla S, De Nucci G: Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results. Biopharm Drug Dispos. 2008 Jan;29(1):17-28. doi: 10.1002/bdd.585. [PubMed:17941060]
  5. Schran HF, McDonald S, Lehr R: Pharmacokinetics and bioavailability of ergoloid mesylates. Biopharm Drug Dispos. 1988 Jul-Aug;9(4):349-61. [PubMed:3207855]
  6. Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.
  7. Pillay V.V. (2013). Modern medical toxicology (4th ed.). Jaypee Brothers.
  8. Barceloux D. (2008). Medical toxicology of natural substances. Wiley. [ISBN:978-0-470-33447-4]
  9. FDA approval [Link]
  10. FDA approval [Link]
  11. Dailymed [Link]
  12. Kegg [Link]
  13. Pharmacopeia [File]
External Links
KEGG Drug
D02268
KEGG Compound
C14055
PubChem Substance
46505963
ChemSpider
60600935
ChEBI
34706
Therapeutic Targets Database
DAP000901
PharmGKB
PA164752439
Wikipedia
Ergoloid
AHFS Codes
  • 12:16.00 — Sympatholytic (Adrenergic Blocking) Agents
MSDS
Download (47.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentDementia, Vascular1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Gallipot
  • Prescript Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral1 mg
Prices
Unit descriptionCostUnit
Ergoloid mesylates powder87.5USD g
Ergoloid mesylates 1 mg tablet1.3USD tablet
Hydergine 1 mg Tablet1.1USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)192 ºC'MSDS'
boiling point (°C)Decomposes'MSDS'
water solubilityPartially soluble'MSDS'
logP2.8HMDB
Predicted Properties
Not Available
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8284
Blood Brain Barrier-0.9494
Caco-2 permeable-0.6447
P-glycoprotein substrateSubstrate0.6838
P-glycoprotein inhibitor IInhibitor0.6581
P-glycoprotein inhibitor IINon-inhibitor0.8001
Renal organic cation transporterNon-inhibitor0.8838
CYP450 2C9 substrateNon-substrate0.75
CYP450 2D6 substrateNon-substrate0.7966
CYP450 3A4 substrateSubstrate0.6681
CYP450 1A2 substrateNon-inhibitor0.7702
CYP450 2C9 inhibitorNon-inhibitor0.7072
CYP450 2D6 inhibitorNon-inhibitor0.9221
CYP450 2C19 inhibitorNon-inhibitor0.6493
CYP450 3A4 inhibitorNon-inhibitor0.7973
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8464
Ames testNon AMES toxic0.6324
CarcinogenicityNon-carcinogens0.6535
BiodegradationNot ready biodegradable0.9321
Rat acute toxicity2.5438 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8821
hERG inhibition (predictor II)Inhibitor0.5783
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Pillay V.V. (2013). Modern medical toxicology (4th ed.). Jaypee Brothers.
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Pillay V.V. (2013). Modern medical toxicology (4th ed.). Jaypee Brothers.
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Pillay V.V. (2013). Modern medical toxicology (4th ed.). Jaypee Brothers.
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...

Components:
References
  1. Pillay V.V. (2013). Modern medical toxicology (4th ed.). Jaypee Brothers.

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kegg [Link]

Drug created on June 13, 2005 07:24 / Updated on May 22, 2018 23:48